December 20, 2012 12:39 — 0 Comments

Methodist Hospital, Remeditex Ventures LLC Developing Brain Tumor Drug

The Methodist Hospital in Houston and Dallas-based Remeditex Ventures LLC have entered into an exclusive agreement to develop an investigational drug for glioblastomas, the most malignant of all primary brain cancers. Current treatments only prolong survival for an average of five months.

The drug MP-MUS was developed by David S. Baskin, MD, and Martyn A. Sharpe, PhD, Department of Neurosurgery researchers at the Methodist Neurological Institute and The Methodist Hospital Research Institute. This novel substance has been shown in recent studies to kill human glioblastoma cells in cell culture and in an animal model. The drug works by selectively targeting mitochondria in glioblastoma cells and destroying mitochondrial activity. Methodist’s sponsored research agreement with Remeditex could help move the drug toward human clinical trials. For more information, click here to read the full release.

Comments are closed.